Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Jun
18
Today In Oncology
New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer
Preclinical Research Shows Interferon May Attenuate Neutrophil Response to Cancer Immunotherapy
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia
Relapsed or Refractory Multiple Myeloma Talquetamab Daratumumab
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo